Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has reported very good numbers in Q2 2022. Those numbers include revenues of $4.8 million, up 80% over Q2-21. Saviuk telling Proactive the company saw gross margins of $1.7 million, up 134% over Q2-21. Saviuk says the numbers are being led by their 3 lead brands, Redesca, Enerzair and Atectura. In fact, Redesca has captured a 54% share of the Canadian low molecular weight heparin biosimilar market.
Valeo Pharma sees 80% increase in revenue year over year as company reports Q2 financials
